Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5151
Pulse Biosciences
PLSE
$3.25B
| $887K | ﹤0.01% |
31,995
-11,170
| -26% | -$264K |
2017 Q1
37 quarters
|
|
5152
Resources Connection
RGP
$94.4M
| $883K | ﹤0.01% |
207,808
-22,151
| -10% | -$93.1K |
2013 Q2
52 quarters
|
|
5153
Neostellar Capital Corp
NSLR
$181M
| $880K | ﹤0.01% |
70,172
+4,286
| +7% | +$56.4K |
2013 Q2
52 quarters
|
|
5154
OFS Credit Co
OCCI
$57.6M
| $879K | ﹤0.01% |
343,451
-39,734
| -10% | -$122K |
2021 Q2
20 quarters
|
|
5155
Ethos Technologies Inc
LIFE
$2.52B
| $879K | ﹤0.01% |
48,457
-955
| -2% | -$17.2K |
2026 Q1
1 quarter
|
|
5156
Direxion Auspice Broad Commodity Strategy ETF
COM
$210M
| $874K | ﹤0.01% |
26,822
+2
| +0% | +$67 |
2021 Q4
18 quarters
|
|
5157
Dimensional International High Profitability ETF
DIHP
$6.5B
| $874K | ﹤0.01% |
25,620
-3,138
| -11% | -$106K |
2023 Q2
12 quarters
|
|
5158
Telos
TLS
$319M
| $874K | ﹤0.01% |
189,920
-29,532
| -13% | -$131K |
2020 Q4
22 quarters
|
|
5159
Goldman Sachs Enhanced U.S. Equity ETF
GUSE
$365M
| $866K | ﹤0.01% |
19,197
-1,303
| -6% | -$56.5K |
2025 Q4
2 quarters
|
|
5160
Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF
ASHS
$29.7M
| $866K | ﹤0.01% |
17,807
-1,834
| -9% | -$81.8K |
2018 Q2
32 quarters
|
|
5161
WisdomTree Europe Quality Dividend Growth Fund
EUDG
$66.5M
| $864K | ﹤0.01% |
22,229
-1,506
| -6% | -$57.6K |
2015 Q1
45 quarters
|
|
5162
EverCommerce
EVCM
$1.68B
| $863K | ﹤0.01% |
85,806
-10,768
| -11% | -$114K |
2021 Q3
19 quarters
|
|
5163
Electrovaya
ELVA
$268M
| $855K | ﹤0.01% |
81,389
+23,023
| +39% | +$228K |
2025 Q3
3 quarters
|
|
5164
Invesco Active US Real Estate Fund
PSR
$55.9M
| $854K | ﹤0.01% |
8,328
-1,524
| -15% | -$154K |
2013 Q2
52 quarters
|
|
5165
International General Insurance
IGIC
$1.04B
| $853K | ﹤0.01% |
32,612
-8,542
| -21% | -$218K |
2020 Q2
24 quarters
|
|
5166
Milestone Pharmaceuticals
MIST
$98.1M
| $851K | ﹤0.01% |
635,211
-88,930
| -12% | -$142K |
2019 Q2
28 quarters
|
|
5167
Invesco Golden Dragon China ETF
PGJ
$84.1M
| $850K | ﹤0.01% |
37,654
-5,168
| -12% | -$133K |
2013 Q2
52 quarters
|
|
5168
iShares MSCI Belgium ETF
EWK
$238M
| $850K | ﹤0.01% |
31,384
-952
| -3% | -$25.1K |
2013 Q2
52 quarters
|
|
5169
CS Disco
LAW
$304M
| $849K | ﹤0.01% |
224,689
-71,907
| -24% | -$279K |
2021 Q3
19 quarters
|
|
5170
Keros Therapeutics
KROS
$220M
| $848K | ﹤0.01% |
79,286
-44,826
| -36% | -$499K |
2020 Q2
24 quarters
|
|
5171
DWS Municipal Income Trust
KTF
$319M
| $848K | ﹤0.01% |
92,132
+31,631
| +52% | +$288K |
2013 Q2
52 quarters
|
|
5172
Cronos Group
CRON
$1.18B
| $847K | ﹤0.01% |
304,527
+54,132
| +22% | +$145K |
2018 Q1
33 quarters
|
|
5173
Contineum Therapeutics
CTNM
$297M
| $846K | ﹤0.01% |
51,618
-19,183
| -27% | -$251K |
2024 Q2
8 quarters
|
|
5174
Liberty Latin America Class A
LILA
$1.62B
| $845K | ﹤0.01% |
107,726
-221,348
| -67% | -$1.23M |
2015 Q3
43 quarters
|
|
5175
Karat Packaging
KRT
$1.08B
| $844K | ﹤0.01% |
25,234
-28,085
| -53% | -$809K |
2021 Q2
20 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.